

Zheng Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11368828/publications.pdf>

Version: 2024-02-01

17
papers

1,378
citations

567281

15
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1714
citing authors

#	ARTICLE	IF	CITATIONS
1	Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling. <i>Cell Reports</i> , 2020, 31, 107809.	6.4	88
2	A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10352-10361.	6.4	6
3	Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator. <i>Hepatology</i> , 2019, 70, 11-24.	7.3	24
4	Identification of New ATG4B Inhibitors Based on a Novel High-Throughput Screening Platform. <i>SLAS Discovery</i> , 2017, 22, 338-347.	2.7	28
5	Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms. <i>Scientific Reports</i> , 2017, 7, 42374.	3.3	103
6	Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3352-3371.	6.4	46
7	Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7651-7666.	6.4	59
8	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 802-806.	2.8	54
9	Targeting Hippo pathway by specific interruption of YAP \leftrightarrow TEAD interaction using cyclic YAP \leftrightarrow like peptides. <i>FASEB Journal</i> , 2015, 29, 724-732.	0.5	115
10	Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP \leftrightarrow TEAD Protein \leftrightarrow Protein Interaction. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 993-998.	2.8	130
11	Automated Structure Refinement for a Protein Heterodimer Complex Using Limited EPR Spectroscopic Data and a Rigid-Body Docking Algorithm: A Three-Dimensional Model for an Ankyrin-CDB3 Complex. <i>Journal of Physical Chemistry B</i> , 2014, 118, 4717-4726.	2.6	8
12	Determination of Structural Models of the Complex between the Cytoplasmic Domain of Erythrocyte Band 3 and Ankyrin-R Repeats 13 \leftrightarrow 24. <i>Journal of Biological Chemistry</i> , 2011, 286, 20746-20757.	3.4	30
13	Antidepressant specificity of serotonin transporter suggested by three Leu \leftrightarrow SSRI structures. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 652-657.	8.2	239
14	LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake. <i>Science</i> , 2007, 317, 1390-1393.	12.6	317
15	Structure of the Cytoplasmic Domain of Erythrocyte Band 3 Hereditary Spherocytosis Variant P327R: \leftrightarrow Band 3 Tuscaloosa. <i>Biochemistry</i> , 2007, 46, 10248-10257.	2.5	17
16	Dipolar Coupling between Nitroxide Spin Labels: The Development and Application of a Tether-in-a-Cone Model. <i>Biophysical Journal</i> , 2006, 90, 340-356.	0.5	58
17	Solution Structure of the Cytoplasmic Domain of Erythrocyte Membrane Band 3 Determined by Site-Directed Spin Labeling \leftrightarrow . <i>Biochemistry</i> , 2005, 44, 15115-15128.	2.5	56